206 related articles for article (PubMed ID: 31752970)
21. MYC in Germinal Center-derived lymphomas: Mechanisms and therapeutic opportunities.
Bisso A; Sabò A; Amati B
Immunol Rev; 2019 Mar; 288(1):178-197. PubMed ID: 30874346
[TBL] [Abstract][Full Text] [Related]
22. MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.
Wang XJ; Medeiros LJ; Lin P; Yin CC; Hu S; Thompson MA; Li S
Am J Surg Pathol; 2015 Sep; 39(9):1250-8. PubMed ID: 25828389
[TBL] [Abstract][Full Text] [Related]
23. Double-Hit Large B Cell Lymphoma.
Khelfa Y; Lebowicz Y; Jamil MO
Curr Oncol Rep; 2017 Sep; 19(11):74. PubMed ID: 28952038
[TBL] [Abstract][Full Text] [Related]
24. Unexpected favorable outcome in a patient with high grade B-cell lymphoma with abnormalities of MYC, BCL6 and BCL2 loci.
Adams T; Fuchs D; Shadoan PK; Johnstone L; Lau BM; McGhan L; Anwer F; Al-Kateb H
Cancer Genet; 2018 Apr; 222-223():25-31. PubMed ID: 29666005
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
[TBL] [Abstract][Full Text] [Related]
26. C-MYC and BCL2: Correlation between Protein Over-Expression and Gene Translocation and Impact on Outcome in Diffuse Large B Cell Lymphoma.
Mohammed AA; Rashed HE; Abdelrahman AE; Obaya AA; Toam M; Abdel Nour HM; Abdelhamid MI; Elsayed FM
Asian Pac J Cancer Prev; 2019 May; 20(5):1463-1470. PubMed ID: 31127909
[TBL] [Abstract][Full Text] [Related]
27. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
Nosrati A; Monabati A; Sadeghipour A; Radmanesh F; Safaei A; Movahedinia S
Ann Hematol; 2019 Jan; 98(1):169-173. PubMed ID: 30306208
[TBL] [Abstract][Full Text] [Related]
28. Double-hit lymphomas: current paradigms and novel treatment approaches.
Dunleavy K
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):107-12. PubMed ID: 25696842
[TBL] [Abstract][Full Text] [Related]
29. Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas.
Testo N; Olson LC; Subramaniyam S; Hanson T; Magro CM
Am J Dermatopathol; 2016 Oct; 38(10):769-74. PubMed ID: 27391453
[TBL] [Abstract][Full Text] [Related]
30. TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations.
Gebauer N; Bernard V; Gebauer W; Thorns C; Feller AC; Merz H
Leuk Lymphoma; 2015 Jan; 56(1):179-85. PubMed ID: 24679006
[TBL] [Abstract][Full Text] [Related]
31. CRISPR-Cas9 Screening of Kaposi's Sarcoma-Associated Herpesvirus-Transformed Cells Identifies XPO1 as a Vulnerable Target of Cancer Cells.
Gruffaz M; Yuan H; Meng W; Liu H; Bae S; Kim JS; Lu C; Huang Y; Gao SJ
mBio; 2019 May; 10(3):. PubMed ID: 31088931
[TBL] [Abstract][Full Text] [Related]
32. Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas.
Drexler HG; Eberth S; Nagel S; MacLeod RA
Leuk Lymphoma; 2016 May; 57(5):1015-20. PubMed ID: 26727417
[TBL] [Abstract][Full Text] [Related]
33. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.
Herrera AF; Mei M; Low L; Kim HT; Griffin GK; Song JY; Merryman RW; Bedell V; Pak C; Sun H; Paris T; Stiller T; Brown JR; Budde LE; Chan WC; Chen R; Davids MS; Freedman AS; Fisher DC; Jacobsen ED; Jacobson CA; LaCasce AS; Murata-Collins J; Nademanee AP; Palmer JM; Pihan GA; Pillai R; Popplewell L; Siddiqi T; Sohani AR; Zain J; Rosen ST; Kwak LW; Weinstock DM; Forman SJ; Weisenburger DD; Kim Y; Rodig SJ; Krishnan A; Armand P
J Clin Oncol; 2017 Jan; 35(1):24-31. PubMed ID: 28034071
[TBL] [Abstract][Full Text] [Related]
34. XPO1-dependent nuclear export as a target for cancer therapy.
Azizian NG; Li Y
J Hematol Oncol; 2020 Jun; 13(1):61. PubMed ID: 32487143
[TBL] [Abstract][Full Text] [Related]
35. Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas.
Sarkozy C; Traverse-Glehen A; Coiffier B
Lancet Oncol; 2015 Nov; 16(15):e555-e567. PubMed ID: 26545844
[TBL] [Abstract][Full Text] [Related]
36. Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma.
Oliveira CC; Maciel-Guerra H; Kucko L; Hirama EJ; Brilhante AD; Quevedo FC; da Cunha IW; Soares FA; Niero-Melo L; Dos Reis PP; Domingues MA
Diagn Pathol; 2017 Jan; 12(1):3. PubMed ID: 28061782
[TBL] [Abstract][Full Text] [Related]
37. Altered pathways and targeted therapy in double hit lymphoma.
Zhuang Y; Che J; Wu M; Guo Y; Xu Y; Dong X; Yang H
J Hematol Oncol; 2022 Mar; 15(1):26. PubMed ID: 35303910
[TBL] [Abstract][Full Text] [Related]
38. Inferior survival in high-grade B-cell lymphoma with
McPhail ED; Maurer MJ; Macon WR; Feldman AL; Kurtin PJ; Ketterling RP; Vaidya R; Cerhan JR; Ansell SM; Porrata LF; Nowakowski GS; Witzig TE; Habermann TM
Haematologica; 2018 Nov; 103(11):1899-1907. PubMed ID: 29903764
[TBL] [Abstract][Full Text] [Related]
39. Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations.
Johnson SM; Umakanthan JM; Yuan J; Fedoriw Y; Bociek RG; Kaiser-Rogers K; Sanmann JN; Montgomery ND
Hum Pathol; 2018 Oct; 80():192-200. PubMed ID: 29902576
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
